Payload Information
General Information of This Payload
| Payload ID | PAY0LFXNZ |
|||||
|---|---|---|---|---|---|---|
| Name | B63 |
|||||
| Synonyms |
B63
Click to Show/Hide
|
|||||
| Target | Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) | |||||
| Structure |
|
|||||
| Formula | C27H30ClN5O5 |
|||||
| Isosmiles | O=C1C(C=CC(CNC(NC(C=C2)=CC(Cl)=C2CCCOC3CNC3)=O)=C4)=C4CN1C(CCC5=O)C(N5)=O |
|||||
| InChI |
InChI=1S/C27H30ClN5O5/c28-22-11-19(5-4-17(22)2-1-9-38-20-13-29-14-20)31-27(37)30-12-16-3-6-21-18(10-16)15-33(26(21)36)23-7-8-24(34)32-25(23)35/h3-6,10-11,20,23,29H,1-2,7-9,12-15H2,(H2,30,31,37)(H,32,34,35)
|
|||||
| InChIKey |
XSSRZNVPRIWHLV-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
540.02 |
Polar area |
128.87 |
||
Complexity |
1216.594577 |
xlogp Value |
2.3437 |
|||
Heavy Count |
38 |
Rot Bonds |
9 |
|||
Hbond acc |
6 |
Hbond Donor |
4 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
NCI-H929 cells
|
Plasma cell myeloma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
NCI-H929 cells
|
Plasma cell myeloma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | 10-50 | nM |
Ramos cells
|
Burkitt lymphoma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | 10-50 | nM |
Ramos cells
|
Burkitt lymphoma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | 10-50 | nM |
NCI-H82 cells
|
Lung small cell carcinoma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | 10-50 | nM |
NCI-H82 cells
|
Lung small cell carcinoma
|
[1] |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
wO2024222841A1 ADC66 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
6.613 pM
|
High CD33 expression (CD33+++) | ||
| Method Description |
Cytotoxicity of ADC to MV4-11 cells
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
wO2024222841A1 ADC65 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
6.699 pM
|
High CD33 expression (CD33+++) | ||
| Method Description |
Cytotoxicity of ADC to MV4-11 cells
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
wO2024169913A1 ADC01-06-4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.02107 nM
|
High HER2 expression (HER2+++) | ||
| Method Description |
Cytotoxicity of ADC to SK-BR-3 cells
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
wO2024169913A1 ADC04-07-8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.04488 nM
|
High DLL3 expression (DLL3+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-H82 cells
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H82 cells | CVCL_1591 | ||